Sangamo Therapeutics Inc Says Pfizer Expects A Pivotal Readout In The Phase 3 Affine Trial Evaluating Giroctocogene Fitelparvovec In The Middle Of 2024
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics Inc has announced that Pfizer expects a pivotal readout in the Phase 3 Affine trial evaluating Giroctocogene Fitelparvovec in the middle of 2024, according to an SEC filing.
November 03, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's expected readout in 2024 for the Phase 3 trial, as announced by Sangamo, could potentially impact the company's stock price and future product pipeline.
The expected readout in 2024 for the Phase 3 trial is a significant event for Pfizer. However, the impact on the stock price is uncertain as it depends on investor sentiment and market conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Sangamo's announcement of Pfizer's expected readout in 2024 for the Phase 3 trial could potentially impact investor sentiment and the company's stock price.
The announcement of the expected readout in 2024 for the Phase 3 trial is a significant event for Sangamo. However, the impact on the stock price is uncertain as it depends on investor sentiment and market conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100